Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.69 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559918 | 0.92 | EGFR (0.81) | EGFRERBB2ADORA3DOT1LDPP4 | |
| SCHEMBL19800490 | 0.92 | EGFR (0.81) | EGFRERBB2ADORA3DOT1LDPP4 | |
| SCHEMBL2115819 | 0.91 | EHMT1 (0.71) | EGFRERBB2ADORA3DOT1LDPP4 | |
| SCHEMBL12222453 | 0.90 | DOT1L (0.80) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| SCHEMBL21160482 | 0.90 | DOT1L (0.80) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| SCHEMBL13637925 | 0.90 | DOT1L (0.80) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| SCHEMBL12899832 | 0.90 | DOT1L (0.80) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| SCHEMBL18430888 | 0.90 | DOT1L (0.80) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| SCHEMBL5066267 | 0.90 | DOT1L (0.80) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| SCHEMBL9550945 | 0.90 | DOT1L (0.80) | ADORA3DOT1LDPP4MEN1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026088246-A1 | METHOD FOR PRODUCING LOW-MOLECULAR-WEIGHT COMPOUND | ＮＴＴ株式会社 | 2026-04-30 | — | — | WO | claimed |
| US-20200113943-A1 | METHODS FOR ENHANCED PRODUCTION AND ISOLATION OF CELL-DERIVED VESICLES AND TREATMENT OF INFLAMMATION AND NEUROLOGICAL DAMAGE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-04-16 | — | — | US | claimed |
| US-20190008902-A1 | METHODS FOR ENHANCED PRODUCTION AND ISOLATION OF CELL-DERIVED VESICLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-10 | — | — | US | claimed |
| WO-2018226758-A2 | METHODS FOR ENHANCED PRODUCTION AND ISOLATION OF CELL-DERIVED VESICLES AND TREATMENT OF INFLAMMATION AND NEUROLOGICAL DAMAGE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-13 | — | — | WO | claimed |
| EP-3397264-A1 | METHODS FOR ENHANCED PRODUCTION AND ISOLATION OF CELL-DERIVED VESICLES | The Regents of The University of California (US) | 2018-11-07 | — | — | EP | claimed |
| US-20180271891-A1 | SELECTIVE TREATMENT OF PRMT5 DEPENDENT CANCER | THE BROAD INSTITUTE, INC. | 2018-09-27 | — | — | US | claimed |
| EP-3268044-A2 | PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER WITH REDUCED MTAP ACTIVTY | The Broad Institute Inc. (US) | 2018-01-17 | — | — | EP | claimed |
| WO-2017117585-A1 | METHODS FOR ENHANCED PRODUCTION AND ISOLATION OF CELL-DERIVED VESICLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-06 | — | — | WO | claimed |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| WO-2016145150-A2 | SELECTIVE TREATMENT OF PRMT5 DEPENDENT CANCER | The Broad Institute Inc. (US) | 2016-09-15 | — | — | WO | claimed |
| EP-0555352-A1 | AGENTS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA AND NEOPLASTIC DISEASES | HEALTH RESEARCH, INC. (US) | 1993-08-18 | — | — | EP | claimed |
| EP-0526866-A1 | The use of adenosine compounds for the preparation in the treatment of ischaemia | BIORESEARCH S.p.A. (IT) | 1993-02-10 | — | — | EP | claimed |
| US-5180714-A | ADENOSINE COMPOUNDS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA | HEALTH RESEARCH, INC. (US) | 1993-01-19 | — | — | US | claimed |
| WO-1992007570-A1 | AGENTS FOR THE TREATMENT OF DISEASES CAUSED BY PARASITIC PROTOZOA AND NEOPLASTIC DISEASES | HEALTH RESEARCH, INC. (US) | 1992-05-14 | — | — | WO | claimed |
| US-4973678-A | VASODILATORS, ANALGESICS, ANTIINFLAMMATORY, ANTIPYRETIC, ANTICOAGULANTS | NB JACKETS DE PUERTO RICO (US) | 1990-11-27 | — | — | US | claimed |
| EP-0387757-A2 | Use of 5'-deoxy-5'methylthioadenosine, S-adenosylmethionine and their salts in the preparation of pharmaceutical compositions favouring hair growth in subjects suffering from baldness | BIORESEARCH S.p.A. (IT) | 1990-09-19 | — | — | EP | claimed |
| EP-0387756-A1 | Use of 5'-deoxy-5'-methylthioadenosine s-adenosylmethionine and their salts in the preparation of seborrhea-reducing pharmaceutical compositions | BIORESEARCH S.p.A. (IT) | 1990-09-19 | — | — | EP | claimed |
| EP-0184248-B1 | SALTS OF 5'-METHYLTHIO-5'-DEOXYADENOSINE WITH LONG-ALKYL CHAIN SULPHONIC ACIDS | BIORESEARCH S.p.A. (IT) | 1989-08-02 | — | — | EP | claimed |
| EP-0184248-A2 | Salts of 5'-methylthio-5'-deoxyadenosine with long-alkyl chain sulphonic acids | BIORESEARCH S.p.A. (IT) | 1986-06-11 | — | — | EP | claimed |
| US-4373097-A | Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity | BIORESEARCH S.R.L. (IT) | 1983-02-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | EGFR 411/4885ERBB2 494/4885ADORA3 1476/4885 |
| US-20180271891-A1 | SELECTIVE TREATMENT OF PRMT5 DEPENDENT CANCER | PRMT5, PRMT1, PRMT6 | EGFR 2842/4885ERBB2 3456/4885ADORA3 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.